Articles tagged with Cancer Patients
A collaborative research team from Dartmouth and Honduras found a high level of participation in rural cancer screening events, resulting in over 88% of identified individuals seeking follow-up care. The 'multiphasic' approach involved multiple cancer screenings in one event, which was well-received by local communities.
Researchers at UC have discovered a mechanism that could lead to new immunotherapies for patients with head and neck cancers. By understanding how calmodulin interacts with ion channels in immune cells, scientists may be able to develop new treatments to restore the ability of these cells to enter and kill tumors.
A new genetic test can identify patients with multiple myeloma who are at 'ultra high risk' of their cancer progressing aggressively early on. These patients have poorer survival rates and are unlikely to benefit from lenalidomide alone, highlighting the need for alternative treatment approaches.
The National Comprehensive Cancer Network (NCCN) has published a list of high-impact measures for assessing quality improvements in cancer care. The recommendations reflect a landscape analysis from leading oncology experts and include endorsement of 15 existing measures and seven new concepts proposed for development.
A self-paced online program guides adult cancer patients and older adults through advance care planning, improving their knowledge, decision-making skills, and readiness. Participants took modest action to begin planning, suggesting that such tools could support advance care planning initiatives in outpatient settings.
Research reveals bias and stereotyping among healthcare professionals when recruiting patients for cancer clinical trials. The study highlights language barriers, misconceptions, and negative perceptions of minority participants as challenges. Experts call for culturally tailored approaches to address biases in clinical trial recruitment.
Research by German Cancer Research Center and Hebrew University finds that intestinal bacteria reprogram DNA activity in gut mucosa cells, controlling healthy gut development and inflammation. Demethylating enzymes TET2 and TET3 play a key role in this process.
The Pancreatic Cancer Collective has awarded $16 million to four research teams pursuing preclinical work and clinical trials for new pancreatic cancer treatments. These breakthroughs aim to improve the five-year survival rate of 9%.
Researchers used AI to analyze digitized images of cancer tissues and found critical variations between black and white male patients, which could improve care for black patients with prostate cancer. The study suggests that there are biological differences in the disease that cannot be explained by other disparities.
A new testing method combining systematic biopsy with MRI-targeted biopsy leads to more accurate diagnoses and better treatment outcomes for prostate cancer patients. The study found that combined biopsy provided more accurate diagnoses than MRI-targeted biopsies alone, reducing the risk of overtreatment and undertreatment.
A new study found improvements in five-year survival rates for all cancers in young adults, with some cancer types showing little to no improvement since the 1970s. Treatment advances have led to steady improvements in estimated survival rates among adolescents and young adults.
A recent study has found that the five-year survival rate for adolescents and young adults with certain types of cancer has improved substantially over the past three decades. Leukemia and non-Hodgkin lymphoma have seen significant declines in mortality rates, with improvements ranging from 20-30 percentage points between 1975 and 2005.
A new clinical trial suggests that immunotherapy given before surgery for oral cavity cancers can elicit an immune response that shrinks tumors. Most patients (52%) experienced a clinical reduction of their primary tumor after immunotherapy, and four patients had more than 90% pathologic response.
A targeted therapy drug, everolimus, has been shown to extend progression-free survival for advanced head and neck cancer patients. Patients with TP53 mutations experienced a significant survival benefit, indicating potential as a treatment option for high-risk patients.
A study at MD Anderson Cancer Center found that using MLN4924 and dual treatment with anti-PD1 can induce durable, curative responses in patients with MMR-deficient and MSI cancers. The therapy approach shows promise as a novel therapeutic vulnerability for this type of cancer.
A novel blood test using gold nanoparticles detects cancer-derived extracellular vesicles, enabling earlier diagnosis and better treatment tracking. The technology has been successfully tested on melanoma patients and shows promise as a potential complement to existing cancer imaging technologies.
A new study finds that common malnutrition definitions do not apply equally to all cancers, highlighting the need for cancer-type specific definitions for preoperative risk assessment. The study's findings suggest that using one-size-fits-all definitions could result in overestimating or underestimating a patient's risk of complication...
A clinical trial led by Queen Mary University of London found that immune therapy drug pembrolizumab significantly reduced the risk of cancer recurrence in patients with early triple negative breast cancer. Nearly 65% of women showed no sign of cancer after treatment, compared to 51% on chemotherapy alone.
Researchers from CNIO and Cabimer reveal DNA topological problems cause endogenous DNA breaks leading to lymphoma development. The study highlights a strong causal relationship between topological problems and cancer development in ATM-deficient lymphoid malignancies.
A clinical trial has found that a combination of ipilimumab and nivolumab immunotherapies can shrink tumors in 44% of patients with high-grade neuroendocrine cancer. The trial, DART, offers new hope for rare cancer treatment, which accounts for almost a quarter of all cancers diagnosed worldwide.
Dr. John E. Dick has been honored with the 2020 Pezcoller-AACR Award for his discovery of leukemic stem cells and development of a hematopoietic xenograft assay. This work has provided crucial insights into leukemia progression and potential therapeutic targets.
Researchers at Yale Cancer Center discovered that a small amount of the PD-L1 biomarker can predict long-term survival benefits from using pembrolizumab in patients with advanced lung cancer. The study found that overall survival was about 99% one year after discontinuing treatment, and ranged from 23% to 35% three years after treatment.
A protein called interleukin 6 (IL-6) plays a significant role in the spread of colorectal cancer to other parts of the body, particularly the liver. Suppressing IL-6 expression can enhance anti-tumor immune functions and improve patient survival.
Researchers found that both strands of microRNA coordinate to act on the same cancer pathways, driving aggressiveness and growth. MicroRNAs miR-30a and miR-145 were identified as key players in keeping cancers in check, impacting patient survival.
This observational study analyzed 112 studies to examine the association between cancer risk in patients with psoriasis or psoriatic arthritis. The findings suggest that these patients may be at higher risk of specific cancers, including melanoma and non-melanoma skin cancers.
Adult lymphoma patients treated with CAR-T therapy reported improved physical and social function, as well as better emotional and mental health. The study suggests that CAR-T may not only extend survival but also improve quality of life after treatment.
Researchers found that white patients received earlier treatment and had better survival rates than black patients, with hospitals having a significant impact on outcomes. The study suggests structural issues at the hospital level influence differences in cancer outcomes across racial groups.
For the first time, a cancer patient has given birth to a healthy baby using lab-matured eggs that were frozen, thawed, and fertilized five years later. The breakthrough achievement demonstrates the potential of in vitro maturation (IVM) for fertility preservation in cancer patients.
Researchers developed a hydrogel that changes color with radiation exposure, allowing for painless dose monitoring on the skin. The gel is relatively inexpensive and can be used directly on the skin without complex handling.
A new study provides an unprecedented look at the molecular steps of endometrial cancer, offering insights into tumor aggressiveness and patient responses to treatment. The research also suggests potential new roles for already-approved drugs targeting proteins like CDK12, SMARCA4, and PML in other types of cancer.
Researchers identified 34 patients with therapy-associated polyposis (TAP), developing colorectal growths despite not having a hereditary susceptibility. The study found TAP mimics familial polyposis but is biologically distinct, suggesting multiple biological pathways involved in its development.
Researchers found that oral cancers can reprogram nerves to grow into tumors, changing their function and fuelling growth. The team discovered that adrenergic nerves, involved in stress response, are susceptible to drugs used to treat high blood pressure and irregular heartbeats.
Researchers analyzed genomes of nearly 50 tumor samples from angiosarcoma patients and found dozens of mutated genes, including new clues about therapeutic possibilities for some subtypes. The study suggests that drugs approved for other types of cancer might be useful in treating angiosarcoma.
Researchers at Huntsman Cancer Institute developed a novel CAR T cell therapy targeting CD229, a molecule present on cancer cells and stem cells in patients with multiple myeloma. Laboratory tests showed promising results, including the ability to kill mature multiple myeloma cells and myeloma stem cells.
Researchers have shown that patients with low rectal cancer can safely choose to postpone invasive surgery after a course of radio- and chemotherapy. In fact, the majority of patients do not show regrowth of the tumor after two years of surveillance, and those who do, achieve similar outcomes as immediate surgery.
A new study found that breast cancer treatment among women who test positive for an inherited genetic mutation is less in line with practice guidelines, particularly for radiation therapy and chemotherapy. The researchers found distinct differences in surgery, radiation, and chemotherapy treatments among BRCA-positive patients.
A study of 125,500 Danish patients with atrial fibrillation found that those who experienced bleeding were between 11 and 24 times more likely to be diagnosed with bowel cancer. Patients who had gastrointestinal bleeding should always be offered meticulous clinical examination regardless of anticoagulant treatment.
This study found that the addition of nimotuzumab to weekly cisplatin-radiation significantly improves outcomes, including overall survival, in locally advanced head and neck cancer patients with HPV negative oropharyngeal cancers. The study compared these outcomes with a control group receiving only cisplatin-radiation.
Researchers have successfully edited immune cells using CRISPR technology in a U.S. clinical trial, demonstrating sustained anti-tumor function and persistence of the edited cells for up to nine months. The approach has shown promise as a potential treatment for various diseases previously untreatable or incurable.
Researchers have identified new genetic drivers of cancer in non-coding regions of the genome, finding that many cancers are driven by mutations in these areas. The study confirmed previously reported drivers and invalidated others, while also identifying novel putative driver rearrangements near genes called AKR1C.
A recent study published in Geriatrics & Gerontology International found that cancer patients with dementia were less likely to achieve a good death compared to those without. The study's authors emphasize the importance of enhancing end-of-life care discussions and improving symptom management for these patients.
A study of over 2,500 tumor genomes reveals that most cancer cells use alternative mechanisms to lengthen their telomeres, increasing their lifespan. The researchers discovered unique variations in these telomere sequences and their integration into the genome, which may hold clues for developing targeted treatments.
Researchers have identified 81 distinct mutational signatures in human cancer genomes that can help reveal the origins and development of various types of cancer. These signatures can provide insight into factors that have mutated a cell's genetic material and inform new strategies to prevent, diagnose and treat the disease.
The Pan-Cancer Project has created the most comprehensive map of cancer genomes to date, improving our understanding of cancer and its diagnosis. Researchers have identified key regions controlling gene expression and discovered a 'carbon dating' method to pinpoint mutations in tumors years before they appear.
Researchers found CNVs to be genomic modifiers of ASD/DD risk in individuals with PHTS, providing insight into the disorder's clinical outcomes and potential predictors for medical management. The study suggests CNV burden analysis may aid in predicting clinical outcomes for other clinically heterogeneous disorders.
Researchers have established new guidelines for analyzing patient-reported outcomes (PROs) in cancer clinical trials, aiming to provide more consistent and comparable Quality of Life (QoL) results. The adoption of these standards will ensure that trial results are more reliable and beneficial for patients.
A University of Colorado Cancer Center study found that patients with locally advanced rectal cancer who received lower-than-recommended doses of neoadjuvant chemotherapy experienced a complete response and tumor shrinkage similar to those receiving the full dose.
Research found that high CO2 levels drive the aggressiveness of pancreatic tumor cells and their resistance to treatment. Increasing CO2 levels in cell cultures also showed increased growth and aggression, while common chemotherapeutic agents and radiation therapy were less effective against high-CO2-cultured cells.
A long-term follow-up study found that psilocybin therapy significantly improves emotional and existential distress in cancer patients, with sustained benefits lasting nearly five years. The study's results suggest that psilocybin may provide a useful tool for enhancing the effectiveness of psychotherapy.
A new research team will focus on detecting gastric cancer at an early stage, potentially saving thousands of lives. The team will use advanced technologies to identify biomarkers in the blood that indicate the presence of gastric cancer.
New research from UT Southwestern Medical Center shows how AI can generate optimal treatment plans in near real-time, streamlining the process and reducing delays of up to a week. This can decrease the odds of cancer spreading by 12-14%.
SU2C's new health equity initiative aims to reduce racial and ethnic disparities in cancer research, addressing socio-economic, cultural, trust barriers that prevent minority participation. The organization requires grant proposals to include diverse patient recruitment and retention plans.
Researchers have discovered a two-drug combo that can counter resistance to a promising new breast cancer therapy. The combination of neratinib and everolimus effectively blocks the growth of cancer cells with HER2 mutations, providing a novel treatment option for patients with these types of cancers.
The GW Cancer Center is conducting a phase II clinical trial examining the safety and effectiveness of Libtayo in reducing tumor size and preventing recurrence in high-risk cutaneous squamous cell carcinoma. The study aims to enroll over 75 participants and build on preliminary results from similar trials.
The European Parliament has launched a new report on radioligand therapy, highlighting its potential to improve targeted cancer care. The report identifies barriers to adoption and recommends increasing multidisciplinary care and boosting real-world data collection.
Researchers found that only 0.1% of cancer patients were enrolled in clinical trials as their first course of therapy after diagnosis. White males with private health insurance and metastatic cancers are more likely to enroll, but the low enrollment rate is still troubling due to the potential for increased life expectancy.
Researchers at Cardiff University have discovered a new type of killer T-cell with a unique T-cell receptor (TCR) that recognizes and kills most human cancer cells while ignoring healthy cells. This breakthrough has the potential to create a 'one-size-fits-all' cancer therapy, targeting a wide range of cancers in all patients.
A new algorithm uses machine learning to identify genes that spur tumor growth by linking DNA mutations to altered functionality. The method can predict and validate cancer-driving genes in any database or real population sample.
A research team at Dartmouth's Norris Cotton Cancer Center has identified VISTA as a molecule that regulates immunity and limits the damage it can cause. Blocking VISTA may enhance the host's ability to make protective tumor-specific immune responses, leading to potential therapeutic response to cancer.
New research suggests lactate is a catalyst that triggers cancer forming process in mutated cells. The study's findings open a new door to better understand cancer at the metabolic level and could lead to targeted therapies.